New download on ChatGPT available! https://t.co/mZc5Ex2vU9 https://t.co/DyfZepwFOD

Do I have Arthritis? How I handle this frequent curbside consult question... https://t.co/uX6MUfy59w https://t.co/kYviOhcLQj

Metanalysis of CNS Lupus, 44 studies, 17 865 early- (<50y) vs 2970 late-onset SLE (>50y) pts. CNS LE in 16%, more common in younger LE (OR: 1.41). Early-LE had more seizures (OR: 1.68), psychosis (OR: 1.72). Older - more Peripheral neuropathy (OR: 0.64) https://t.co/XoJjIH69t6 https://t.co/sRyV7A07gA

Biomarker Predicts Survival in Autoimmune Lung Disease One major subgroup of patients with ILD arising from polymyositis/dermatomyositis (PM/DM) survived significantly longer when serum levels of interferon-λ3 were relatively low, researchers found. https://t.co/9c9DjOIeoI https://t.co/fBpvjODybd

In Norway incidence of #SLE is decreasing, esp in women 50-59 years. Population study of 1558 confirmed SLE; 797 had new-onset betw 1999-2017. In older women 50-59 yrs incidence fell 3.4 to 1.1/100K (also 74% reduction in menopausal HRT https://t.co/Z1falNwLlD https://t.co/bJ3cXKueKg

Small study of 33 #AAV pts and 21 controls shows nailfold capillaroscopy of no value in diagnosing/assessing AAV pts. https://t.co/uRFDBbLVJq https://t.co/pVETSFlBsp

Poorly documented Dz activity in SpA. AI EHR analysis of 3 Hospitals found 758 pts (328 axSpA, 365 PsA, 65 non-classified SpA). Only 35% axSpA had ASDAS or BASDAI. DAPSA or DAS-28 in only 17% PsA. TJC/SJC in ~20% axSpA & ~32% of PsA https://t.co/OrLdK5k2lN https://t.co/bKjancBG4r

Wallace et al. Dose, duration, recency dependent relationship between GC and MACE. Even 5mg/day, 30 day use, and use 1 year prior associated with risk. 5mg, 7.5mg, 10mg pred for 90 days - 13%, 19%, 27% MACE increase Abstr#2430 #ACR23 #ACRbest https://t.co/zJ9583vllj https://t.co/M1oKAcnqSH

There is a dose, duration and recency-dependent relationship between previous GC use and MACE. GC doses 5mg/day, durations of 30 days, and use one year prior to MACE were all associated with an increased risk of MACE, Wallace B Abst#2430 #ACR23 #ACRBest https://t.co/RdLUvW3W7v https://t.co/CcQXQYwu7J

Marketscan claims data shows Frailty as predictor for serious infxn in RA pts Rx w/ b/tsDMARDs. Among 57,980 RA pts (age 48 yrs), 6% were "frail" - this assoc w/ increased risk of serious infections (aHR 1.5) & inpatient hosp (1.4)https://t.co/cvcqE3KQmV https://t.co/We9uwMdt5Y

Anti-TNF mAbs, JAKi & anti-IL17 Rx appear protective against anterior Uveitis in AxSpA pts. Network Metanalysis of 44 trials, AU IR -TNF mAb: 4.1, ETN: 5.4, IL17i: 2.8, JAKi: 1.5, & placebo: 10.8. AU risk: TNFi < JAKi < IL-17i < ETN << PBO https://t.co/uRYKmtUdsZ https://t.co/5XdBVDfgYV

Chinese Phase 2b RCT of telitacicept (TACI-Fc fusion protein inhibits both BAFF & APRIL) 3 doses vs PBO in 249 active SLE pts. Wk 48 SRI-4 response favored TELI (76% 240 mg, 68% 160 mg, 71% 80 mg vs 34% w/ PBO (all p<0.001) https://t.co/fz4W1le4Db https://t.co/0mTC4gQcdr